TORONTO, Ontario — January 13, 2026 — Leads & Copy — Conavi Medical Corp. (TSXV: CNVI) has closed its previously announced equity offering for gross proceeds of approximately $12 million.
The medical device company intends to use the net proceeds from the Offering to obtain US FDA 510(k) clearance of the next generation Novasight Hybrid system, as well as initiate a targeted market release in the United States. The Company also intends to use the net proceeds for working capital and other general corporate purposes.
Bloom Burton Securities Inc. acted as sole and exclusive agent for the Offering. Under the Offering, subscribers purchased a total of 26,666,670 common shares of the Company at a price of $0.45 per Common Share, for gross proceeds of $12,000,001.50.
“This Offering positions Conavi to initiate a targeted market release of Novasight, following U.S. FDA clearance,” said Tom Looby, President and Chief Executive Officer of Conavi. “The strong participation from U.S. strategic healthcare investors reflects confidence in our technology and commercial strategy, as well as growing interest in intravascular imaging technologies. The proceeds will support our commercialization efforts and continued advancement of our intravascular imaging platform.”
In Canada, the Common Shares purchased pursuant to the Offering were qualified for sale by way of an amended and restated short form prospectus dated January 7, 2026, which was filed in British Columbia, Alberta and Ontario. The Common Shares were also purchased by way of private placement in the United States, pursuant to exemptions from the registration requirements under the U.S. Securities Act of 1933, and pursuant to all applicable U.S. state securities laws.
The Agent received a total cash commission of $701,479.49 and 1,558,843 compensation options of the Company. Each Compensation Option entitles the holder to buy one Common Share at a price of $0.45 per Common Share until expiry on January 13, 2028.
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The first-generation Novasight Hybrid™ System has 510(k) regulatory clearance in the U.S., Canada, China, and Japan.
Contact:
Chief Financial Officer: Mark Quick, 416-483-0100
Investors: Christina Cameron, 416-483-0100 ext.121, IR@conavi.com
Source: Conavi Medical
